Condition (MeSH)
Disease Progression
ClinicalTrials.gov lists 584 trials for Disease Progression or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
399 of the 584 trials are tagged with Disease Progression itself; the rest are tagged with a narrower condition beneath it.
When did Disease Progression trials start? (32)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 46
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 52 |
| 2025 | 42 |
| 2024 | 33 |
| 2023 | 32 |
| 2022 | 36 |
| 2021 | 34 |
| 2020 | 46 |
| 2019 | 37 |
| 2018 | 21 |
| 2017 | 21 |
Showing 10 of 32 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 61 trials starting in 2026 and about 47 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 55 trials still running at the 2026-10-09 snapshot; registered median of 33 months across 260 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Disease Progression trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 29 |
| Phase 1/2 | 18 |
| Phase 2 | 91 |
| Phase 2/3 | 4 |
| Phase 3 | 36 |
| Phase 4 | 19 |
| Not applicable | 105 |
| Observational | 281 |
| Expanded access | 1 |
How many Disease Progression trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 49 |
| Recruiting | 105 |
| Enrolling by invitation | 4 |
| Active, not recruiting | 41 |
| Completed | 225 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Disease Progression trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 12 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 12 |
| AstraZeneca | 5 |
Which drugs are being tested for Disease Progression? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 5 |
| PEMBROLIZUMAB | 5 |
| NAB paclitaxel | 4 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| or carboplatin | 6 |
| MRI | 6 |
| Gemcitabine/Gemzar | 5 |
| Cisplatin 1 | 4 |
| Bortezomib SC | 4 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Disease Progression trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Invasive cancer of any type | 1,617 | 1 |
| Major cardiovascular event | 805 | 1 |
| Gastrointestinal bleeding | 744 | 1 |
| Prostate cancer (in men) | 402 | 1 |
| Myocardial infarction | 369 | 6 |
Showing 5 of 10 adverse events.
Which publications cover Disease Progression? (12,792)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Complex regional pain syndrome evolution is determined by both biological and psychosocial factors: a 1-year prospective observational study. | Pain | 2026 | Yes |
| Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials. | Neurology | 2025 | Yes |
| Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis. | Annals of clinical and translational neurology | 2025 | Yes |
| Predicted natural progression as an Alzheimer's prognostic covariate improves the precision of lecanemab efficacy assessments and clinical trial efficiency. | Alzheimer's & dementia : the journal of the Alzheimer's Association | 2025 | Yes |
| Progression of Coronary Artery Calcification and Risk of Clinical Events in CKD: The Chronic Renal Insufficiency Cohort Study. | American journal of kidney diseases : the official journal of the National Kidney Foundation | 2025 | Yes |
Showing 5 of 12,792 publications.
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.